Functional characterization of BTK C481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia

(2014) J. R. Brown et al.   BLOOD

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

(2014) Jennifer A. Woyach et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib Resistance in Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity

(2013) S Cheng et al.   LEUKEMIA

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

SYK inhibition and response prediction in diffuse large B-cell lymphoma

(2011) S. Cheng et al.   BLOOD

Early Events in B Cell Activation

(2010) Naomi E. Harwood et al.   Annual Review of Immunology

The lymph node microenvironment promotes B-cell receptor signaling, NF- B activation, and tumor proliferation in chronic lymphocytic leukemia

(2010) Y. Herishanu et al.   BLOOD

Activities of SYK and PLC 2 Predict Apoptotic Response of CLL Cells to SRC Tyrosine Kinase Inhibitor Dasatinib

(2010) Z. Song et al.   CLINICAL CANCER RESEARCH

B Cell Signaling and Fate Decision

(2009) Tomohiro Kurosaki et al.   Annual Review of Immunology

Metabolism and Disposition of Dasatinib after Oral Administration to Humans

(2008) L. J. Christopher et al.   DRUG METABOLISM AND DISPOSITION

Early events of B-cell receptor signaling are not essential for the proliferation and viability of AIDS-related lymphoma

(2008) P Lu et al.   LEUKEMIA

Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib

(2008) C Yang et al.   LEUKEMIA